Lack of hypo/hyperglycemic effects of reboxetine in diabetic and non-diabetic rats.
Depression occurs frequently with diabetes affecting the quality of life. All major classes of antidepressants have been shown to have a direct pharmacologic effect on metabolic function, which further worsens glycemic control. There were no reports of effects of reboxetine on glucose and insulin levels. We observed that 21 days administration of reboxetine (2.5 mg/kg, i.p.) in streptozotocin (55 mg/kg, i.p.) induced diabetic and non-diabetic rats produced no significant alteration in glucose levels in diabetic and non-diabetic rats. Serum insulin levels were also not significantly changed by reboxetine (2.5 mg/kg, i.p.). Selective inhibition of noradrenaline reuptake by reboxetine has been suggested to be responsible for lack of effects on glucose and insulin levels.